{"disease":{"id":"implant","name":"implant"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cochlear implants","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cochlear implants","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cochlear implants","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cochlear implantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with cochlear implant.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":30,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00443274","title":"Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56460,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT05645965","title":"Association of Obesity and Cardiovascular Outcomes in Patients With Implantable Cardioverter-defibrillator (ICD)","phase":"","overall_status":"UNKNOWN","enrollment_count":20000,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT07059104","title":"Implant-based Breast Reconstruction in Post-bariatric Women - a Registry-based National Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT05400954","title":"Association of Silicone Breast Implants With Overall Wellbeingand Auto-immune Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT07217236","title":"Proactive Risk Evaluation for Cardiac Implantable Electronic Device Strategy Using AI-ECG","phase":"NA","overall_status":"RECRUITING","enrollment_count":11492,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT04288596","title":"Canadian Adult Congenital Heart Disease Intervention Registry","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":9000,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06332937","title":"Breast Reconstruction","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05302115","title":"S-ICD French Cohort Study (HONEST)","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Paris Sudden Death Expertise Center","has_results":false},{"nct_id":"NCT06187649","title":"Infection After Implant-based Breast Reconstruction","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT07354347","title":"Optimal Settings for Anti Tachycardia Pacing (ATP) on ICD","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3980,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03210883","title":"Global Electrical Heterogeneity and Clinical Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":3471,"lead_sponsor_name":"Larisa Tereshchenko","has_results":false},{"nct_id":"NCT03740425","title":"Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) Study","phase":"","overall_status":"COMPLETED","enrollment_count":3235,"lead_sponsor_name":"G. d'Annunzio University","has_results":false},{"nct_id":"NCT04783818","title":"Adjuvant Radiotherapy's Effect on One and Two Stages Prosthetic Breast Reconstruction and on Autologous Reconstruction","phase":"","overall_status":"COMPLETED","enrollment_count":3200,"lead_sponsor_name":"Humanitas Clinical and Research Center","has_results":false},{"nct_id":"NCT07182799","title":"Starring Optical Coherence Tomography During Percutaneous Coronary Intervention Guidance","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT07352657","title":"Remote Alert Pathway To Optimize CaRe of Cardiac Implantable Electrical Devices: The RAPTOR-CIED Study (Main Phase)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT07461324","title":"Surgeons' Prediction of Dental Surgery Complications and the Influence of Patient Characteristics: Development of an AI Model","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University of Copenhagen","has_results":false},{"nct_id":"NCT03612635","title":"Impact on Patient Outcome of Cardiac Implantable Electronic Device Complications","phase":"","overall_status":"COMPLETED","enrollment_count":2811,"lead_sponsor_name":"Azienda Ospedaliera Cardinale G. Panico","has_results":false},{"nct_id":"NCT07464834","title":"Postcards to Improve Remote Monitoring Connectivity Among Veterans With a Disconnected Monitor","phase":"NA","overall_status":"COMPLETED","enrollment_count":2726,"lead_sponsor_name":"San Francisco VA Health Care System","has_results":false},{"nct_id":"NCT06815068","title":"Effect of Simplified Implant Placement Protocols on Failure Rate","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2700,"lead_sponsor_name":"Chrysalis Dental Center","has_results":false},{"nct_id":"NCT04663893","title":"Peri-Implant and Peri-Prosthetic Fractures: Epidemiology, Morbidity, Mortality, Treatment and Outcome Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Hospital Clínico Universitario de Valladolid","has_results":false},{"nct_id":"NCT05835791","title":"END - VT Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":2454,"lead_sponsor_name":"Nova Scotia Health Authority","has_results":false},{"nct_id":"NCT04579445","title":"Setting a Benchmark for Resource Utilization and Quality of Care in Patients Undergoing TAVI in Europe","phase":"","overall_status":"COMPLETED","enrollment_count":2408,"lead_sponsor_name":"Institut für Pharmakologie und Präventive Medizin","has_results":false},{"nct_id":"NCT06938399","title":"Motiva Implants® Post-Approval Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Motiva USA LLC","has_results":false},{"nct_id":"NCT03579641","title":"Precision Event Monitoring for Patients With Heart Failure Using HeartLogic","phase":"","overall_status":"COMPLETED","enrollment_count":2184,"lead_sponsor_name":"Boston Scientific Corporation","has_results":false},{"nct_id":"NCT04854525","title":"Breast Reconstruction in Previously Irradiated Breast","phase":"","overall_status":"COMPLETED","enrollment_count":2150,"lead_sponsor_name":"Humanitas Clinical and Research Center","has_results":false},{"nct_id":"NCT04255602","title":"A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2120,"lead_sponsor_name":"Shanghai Tong Ren Hospital","has_results":false},{"nct_id":"NCT03620760","title":"Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2036,"lead_sponsor_name":"Xiaofan Wu","has_results":false},{"nct_id":"NCT05899387","title":"Seroma of the Mammary Gland","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital Augsburg","has_results":false},{"nct_id":"NCT06964464","title":"Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT04139616","title":"Prospective Validation of a Pre-Specified Algorithm for the Management of Conduction Disturbances Following TAVR","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","has_results":false},{"nct_id":"NCT06343571","title":"Longitudinal Outcomes in MED-EL Cochlear Implant Recipients Using a FLEX Electrode","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"MED-EL Elektromedizinische Geräte GesmbH","has_results":false},{"nct_id":"NCT05723926","title":"Carotid Implants for PreveNtion of STrokE ReCurrEnce From Large Vessel Occlusion in Atrial Fibrillation Patients Treated With Oral Anticoagulation","phase":"NA","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Javelin Medical","has_results":false},{"nct_id":"NCT01870869","title":"NATRELLE® 410 X-Style and L-Style Breast Implants Continued Access Study","phase":"NA","overall_status":"TERMINATED","enrollment_count":1951,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT02243696","title":"Protego DF4 Post Approval Registry","phase":"","overall_status":"TERMINATED","enrollment_count":1694,"lead_sponsor_name":"Biotronik, Inc.","has_results":true},{"nct_id":"NCT03164408","title":"Orthopaedic Implant Removal","phase":"","overall_status":"COMPLETED","enrollment_count":1545,"lead_sponsor_name":"Universitätsmedizin Mannheim","has_results":false},{"nct_id":"NCT05361759","title":"National Tunisian Registry of Cardiac Implantable Electronic Devices","phase":"","overall_status":"COMPLETED","enrollment_count":1518,"lead_sponsor_name":"Dacima Consulting","has_results":false},{"nct_id":"NCT00598026","title":"Evaluation of the \" Tele-follow-up \" for the Follow-up of Implantable Defibrillators","phase":"NA","overall_status":"COMPLETED","enrollment_count":1501,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT07189728","title":"The MagnaSafe-2 Registry: Assessing the Risks of Magnetic Resonance Imaging in Three Patient Groups","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"The Scripps Research Institute","has_results":false},{"nct_id":"NCT05576194","title":"Taurolidine Containing Antimicrobial CIED Wash to Prevent Infection","phase":"","overall_status":"COMPLETED","enrollment_count":1417,"lead_sponsor_name":"Prof. Dr. Hendrik Bonnemeier","has_results":false},{"nct_id":"NCT03866486","title":"Impact of IntraVascular UltraSound Guidance on the Outcomes of Xience Prime Stents in Long Lesions (IVUS-XPL Study): Retrospective and Prospective Follow-up Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1400,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT07477964","title":"Postcards to Improve Remote Monitoring Connectivity Among Veterans With a Disconnected CIED","phase":"NA","overall_status":"COMPLETED","enrollment_count":1312,"lead_sponsor_name":"San Francisco VA Health Care System","has_results":false},{"nct_id":"NCT04696185","title":"Dapagliflozin After Transcatheter Aortic Valve Implantation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1257,"lead_sponsor_name":"Spanish Society of Cardiology","has_results":false},{"nct_id":"NCT04330898","title":"Patients With Implantable Cardiac Devices Requiring a Nuclear Magnetic Resonance","phase":"","overall_status":"UNKNOWN","enrollment_count":1248,"lead_sponsor_name":"Trialance SCCL","has_results":false},{"nct_id":"NCT05283356","title":"Single Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":1206,"lead_sponsor_name":"Fundacin Biomedica Galicia Sur","has_results":false},{"nct_id":"NCT03833089","title":"Targeted Potassium Levels for Prevention of ICD Therapy","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05798624","title":"Impact of a Previous CS on the Ongoing Pregnancy Rate in Single Euploid Frozen Embryo Transfer (ET)","phase":"","overall_status":"RECRUITING","enrollment_count":1050,"lead_sponsor_name":"ART Fertility Clinics LLC","has_results":false},{"nct_id":"NCT04528277","title":"Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1050,"lead_sponsor_name":"Huashan Hospital","has_results":false},{"nct_id":"NCT04443023","title":"Comparison of Eligible TAVI-valves - Cohort B","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1031,"lead_sponsor_name":"Aarhus University Hospital Skejby","has_results":false},{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06739239","title":"French COhoRte Extra-Vascular Implantable CardiovErter DefibrillatoR","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Paris Sudden Death Expertise Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}